WO2021259397A2 - Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer - Google Patents
Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer Download PDFInfo
- Publication number
- WO2021259397A2 WO2021259397A2 PCT/CU2021/050005 CU2021050005W WO2021259397A2 WO 2021259397 A2 WO2021259397 A2 WO 2021259397A2 CU 2021050005 W CU2021050005 W CU 2021050005W WO 2021259397 A2 WO2021259397 A2 WO 2021259397A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rhegf
- hap
- rp64k
- vaccine composition
- peptides
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 229960005486 vaccine Drugs 0.000 title claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 44
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 35
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 35
- 230000001684 chronic effect Effects 0.000 claims abstract description 9
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 claims abstract description 3
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 46
- 239000002671 adjuvant Substances 0.000 claims description 35
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 29
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 28
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 28
- 229940116977 epidermal growth factor Drugs 0.000 claims description 28
- 230000028993 immune response Effects 0.000 claims description 18
- 239000001509 sodium citrate Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 14
- 229960000814 tetanus toxoid Drugs 0.000 claims description 11
- 230000021615 conjugation Effects 0.000 claims description 10
- 238000005538 encapsulation Methods 0.000 claims description 9
- 239000013110 organic ligand Substances 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052790 beryllium Inorganic materials 0.000 claims description 4
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052684 Cerium Inorganic materials 0.000 claims description 3
- 102000009016 Cholera Toxin Human genes 0.000 claims description 3
- 108010049048 Cholera Toxin Proteins 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000004679 hydroxides Chemical class 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 241000588650 Neisseria meningitidis Species 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 238000002347 injection Methods 0.000 abstract description 15
- 239000007924 injection Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002411 adverse Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 3
- 239000002245 particle Substances 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 25
- 239000010954 inorganic particle Substances 0.000 description 17
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 230000004044 response Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 8
- 230000009881 electrostatic interaction Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008174 sterile solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000568 immunological adjuvant Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241001286462 Caio Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- -1 frown Chemical compound 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Definitions
- the present invention relates to biotechnology, specifically the field of human health.
- it describes new vaccine formulations that contain nano-particulate systems with an immune response against epidermal growth factor, useful for use in cancer therapies.
- EGF epidermal growth factor
- the formulation referred to in patent US 5,894,018, claims the composition of a vaccine to produce an immune response against autologous EGF. It comprises autologous EGF conjugated to a carrier protein (cholera toxin B, tetanus toxoid, a monoclonal antibody, or a Neisseria meningitidis outer membrane protein), administered together with the aluminum hydroxide adjuvant.
- a carrier protein cholera toxin B, tetanus toxoid, a monoclonal antibody, or a Neisseria meningitidis outer membrane protein
- the invention US 8,778,879 describes a vaccine composition for therapeutic use in cancer patients whose active principle is the chemical conjugate between recombinant human EGF (rhEGF) and recombinant protein P64k. It refers to a procedure for the purification of the chemical conjugate that provides it with greater purity and an increase in its immunogenic activity.
- Said composition contains an adjuvant that can be aluminum
- Immunological adjuvants arose from the need to increase the immunogenicity of vaccines developed from recombinant proteins.
- the first adjuvant used was double aluminum sulfate, in 1926.
- various inorganic adjuvants have been evaluated from aluminum, calcium, magnesium, iron, zinc, zirconium, frown, beryllium and silicon.
- aluminum and calcium salts have been approved for use in humans (Paneque-Quevedo A., Applied Biotechnology (2013) 30: 243-249).
- inorganic adjuvants were used in combination with heterologous antigens.
- Aluminum hydroxide and aluminum phosphate are not very appropriate adjuvants to be used in chronic treatments, because aluminum is toxic and poorly metabolized by the human body.
- the impact of aluminum accumulation on human health, specifically on the central nervous, musculoskeletal, respiratory, cardiovascular, endocrine, urinary and reproductive systems has been widely documented (Nayak P., Environmental Research Section A (2002), 89: 101-115; Verstraeten SA et al., Arch Toxicol (2008) 82: 789-802; Flaten TP, Brain Research Bulletin (2001) 2: 187-196).
- CaP calcium phosphates
- US 2,967,802 the mixture of an erysipelas antigen with a hydrated CaP gel is claimed.
- prophylactic vaccines were developed against infections of various pathogenic microorganisms and allergens adsorbed on CaP (US 3,608,071, US 4016252; US 4350686; US 20120121714; Coursaget, P. et al., Infect Immun (1986) 51 (3) : 784-787).
- CaP adjuvants base their immunological effect on the formation of a deposit of antigen that is slowly released, thereby Which allow it to be presented to the immune system for a long time and to generate a response against the inoculated antigen.
- Patent US 8,333,996 claims the development of immune systems formed by the adsorption of antigens such as: Bordetella pertussis, allergens, inactivated human immunodeficiency virus (HIV-2), KLH, vaccines against diphtheria, tetanus toxoid, streptococci, viruses or bacteria Attenuated polio and hepatitis A and B. It also includes DNA adsorption and cytokines, such as granulocyte macrophage colony stimulating factor (GM-CSF).
- GM-CSF granulocyte macrophage colony stimulating factor
- Patent US 6,355,271 claims a method to prepare CaP particles with diameters between 300 and 4000 nm, it is based on the aqueous mixture of calcium chloride, sodium phosphate and sodium citrate for the adsorption of HSV-1 viruses, HSV-2 and EBV, DNA, as well as ovalbumin and Mycobacterium tuberculosis antigens.
- HAp particulate hydroxyapatite systems
- This substance is the main inorganic component of bone tissue, which guarantees its biocompatibility.
- HAp amorphous or with low crystallinity biodegrade in contact with the biological medium.
- the reduction of the size of the particles and the selected material give it superior properties as an adjuvant, with respect to aluminum hydroxide, since they produce a more balanced Th1 / Th2 response and lower generation of IgE-type antibodies (Qing, H. et al.
- a system comprising: a CaP nano-particle core, a biologically active macromolecule encapsulated in the core particle and a surface modifying agent.
- the active biological macromolecule can be a protein, a polypeptide, a polysaccharide, a nucleic acid, a polynucleotide, a lipid or a carbohydrate.
- the invention WO 2003051394 shows a nano-particulate HAp with different types of coatings in a single formulation to be used as an adjuvant.
- nanoparticles are used as carriers of native or recombinant antigens or other pharmacological agents, for their application on the surfaces of the mucosa.
- CaP particles specifically HAp
- rhEGF or one of its peptides and another protein or carrier peptide capable of generating immune responses against EGF are dispensed in a single vial so they do not require additional procedures such as mixtures or emulsions at the time of use.
- the present invention relates to vaccine compositions to induce an immune response against EGF, characterized in that it comprises as an active principle a system that contains rhEGF or its peptides and a carrier protein or peptide linked to a nucleus made up of nano- biodegradable inorganic particles that can be salts, oxides or hydroxides of calcium, iron, zinc, magnesium, zirconium, cerium, beryllium, silicon, or a mixture of two or more of them.
- the inorganic core is made of CaP and more particularly of the HAp type. This HAp is preferably amorphous or of low crystallinity and is partially or totally covered by an organic ligand, particularly sodium citrate.
- the carrier protein or peptide is selected from the group comprising: cholera toxin B, tetanus toxoid, KLH, and Neisseria meningitides P64k.
- the active principle of the vaccine compositions of the present invention is found on the surface of the HAp nano-particles, bound by one of the following methods: Covalent binding of the chemical conjugate of rhEGF or peptides thereof and of the carrier protein or peptide with the HAp nano-particle (HAp-rhEGF-rP64k).
- Covalent binding of rhEGF or peptides thereof and of the protein or carrier peptide with the FIAp nano-particle independently (HAp-PI). Successive covalent binding of rhEGF or peptides thereof and of the carrier protein or peptide to the FIAp nano-particle.
- adjuvants that are selected from the groups that include: Freund's incomplete adjuvants, squalene-based adjuvants, adjuvants of synthetic origin, adjuvants of mineral origin, adjuvants of plant origin, adjuvants. of animal origin, particulate protein adjuvants and liposomes.
- the use of the vaccine compositions described herein for the chronic treatment of cancer is the object of the present invention.
- the object of the present invention is a method of treating a subject in need, which comprises the administration of a therapeutically effective amount of the described vaccine compositions and particularly, with a stage of maintenance of the induction of immune response produced by another EGF vaccine composition.
- the present invention encompasses the synthesis of biodegradable inorganic nanoparticles, coated with organic ligands, chemical activation, as well as covalent binding or by electrostatic interactions with an antigen that induces specific immune response against EGF and its construction on the surface of said particle.
- the present invention comprises the formation of biodegradable inorganic particles, with dimensions in the nanometric, submicron or micrometric scale. These particles are coated with an organic ligand, preferably sodium citrate and are obtained by precipitation, although the present invention is not restricted to said method.
- Biodegradable particles have an inorganic core formed by salts, oxides or hydroxides of calcium, iron, zinc, magnesium, zirconium, cerium, beryllium, silicon, or a mixture of two or more of them. They are preferably formed by CaP, more preferably amorphous HAp, or amorphous HAp with isomorphic substitutions of one or more metals.
- carrier sources of calcium and phosphate ions are used, as well as an organic ligand that gives it a surface charge and a functional group that allows chemical conjugation with biomolecules.
- Consist of biodegradable inorganic particles that can have isomorphic substitutions of metal ions or of another nature.
- Be preferably coated with an organic ligand that gives it a surface charge and functional groups for the conjugation of antigens.
- the inorganic particles obtained under the conditions described above partially or totally coated with an organic ligand containing carboxylate groups, preferably sodium citrate, are activated by adding a binding reagent from the carbodiimide family or another that fulfills similar functions.
- a binding reagent from the carbodiimide family or another that fulfills similar functions.
- reagent / particle mass ratios of 1 to 6 mg / mg are used, with 2 to 5 mg / mg being more recommended.
- the suspension is kept stirred at room temperature (20 ⁇ 5 ° C) for 1-4 h, more recommended 0.5-3 h.
- the activated particles are purified, preferably by means of centrifugation or filtration processes.
- predominantly particles with sizes £ 200 nm, with their surface activated, capable of binding to proteins having exposed functional groups are obtained. This makes them superior to previous developments using inorganic particles for the encapsulation or physical adsorption of active principles.
- the previously activated particles are mixed with the chemical conjugate of the recombinant proteins rhEGF and rP64k, at a mass ratio of rhEGF-rP64k / HAp 1-10 mg / mg, with 2-7 mg / mg being more recommended.
- the above-described reaction produces an amide-type covalent bond between the amino groups (NH 2 ) of the conjugate and the carboxylate groups (COO) on the surface of the particle. Electrostatic interactions also occur between the remaining calcium groups on the surface of HAp and the rhEGF-rP64k conjugate, which is negatively charged and has exposed COO- groups.
- the colloidal suspension is dispersed, preferably with EDTA and finally its pH is regulated to values between 6.7 and 7.3.
- the chemical conjugate of the recombinant rhEGF and rP64k proteins is replaced by the conjugate of rP64k or another carrier protein with one or more rhEGF peptides.
- the system obtained by the covalent binding between the antigen and the inorganic particles is stable and can be stored for long periods, as required by a parenteral formulation. This quality makes it superior to immunotherapeutic systems or drug release systems previously developed from inorganic particles, by the methods of encapsulation or adsorption of active principles.
- the present invention contemplates other options for the construction of systems for the induction of immune response against EGF, through covalent bonds and electrostatic interactions between its components, which are detailed below: Binding of rhEGF or its peptides and of a carrier protein or its peptides to inorganic nanoparticles.
- the HAp / rP64k and HAp / rhEGF mass ratios used are between 1-6 mg / mg, preferably between 2-5 mg / mg.
- the suspension is kept under stirring at room temperature for 1-4 h, 2-3 h more recommended.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- rhEGF is replaced by one or more peptides that are part of rhEGF.
- the suspension is kept under stirring at room temperature for 1-4 h, preferably between 2-3 h.
- the excess rP64k protein is eliminated, it is activated preferably with EDC, then the excess EDC is eliminated and mixed with rhEGF in a proportion of 1-10 mol of rhEGF per mol of rP64k, preferably 2-6 mol of rhEGF per mol of rP64k.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also encompasses the substitution of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- rhEGF is replaced by one or more peptides that are part of rhEGF.
- This procedure generates a system where the carrier protein is bound chemically and by electrostatic interactions with biodegradable inorganic nanoparticles and also with rhEGF.
- This method produces a two-layered rhEGF-rP64k conjugate with high purity, without the presence of free rhEGF or rP64k. It is superior to the conjugate rhEGF-rP64k derived from the inventions US 5,894,018 and US 8,778,879, in which more than 40% of rhEGF is obtained in the free state, without biological relevance. In addition, it reduces the risks associated with the toxicity of the glutaraldehyde used in these inventions.
- a molar ratio of rhEGF / rP64k of 3-9 mol / mol should be used, being more recommended between 4-8 mol / mol.
- the particle / rP64k and particle / rhEGF mass ratios used are between 1-6 mg / mg, being more recommended between 2-5 mg / mg. They are kept stirring at room temperature for 1-4 h, 2-3 h more recommended.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- rhEGF is replaced by one or more peptides that are part of rhEGF.
- a complex matrix of conjugates rhEGF-rP64k is generated and of these with the ligand that covers the inorganic nano-particle. Like the previous systems, it generates an immune response of anti-EGF antibodies. It also reduces by up to 40% the amount of rhEGF necessary for the conformation of the system and reduces the risks associated with the toxicity of the glutaraldehyde used in the inventions US 5,894,018 and US 8,778,879. Formation of systems for the induction of response against EGF by encapsulation or adsorption on the inorganic particle
- the present invention provides methods for synthesizing immunogens that possess an inorganic nucleus and conjugate rhEGF-rP64k or rhEGF and rP64k or their peptides, inside or adsorbed on the surface of the particle.
- Carrier sources of calcium and phosphate ions are mixed in aqueous solution, ensuring to maintain a cation / anion molar ratio of 1.4-3.5.
- the rhEGF-P64k conjugate is added, at a mass ratio of rhEGF-rP64k / inorganic nano-particle of 1-10 mg / mg, with 2-7 mg / mg being more recommended.
- ammonium hydroxide or sodium hydroxide is added until pH 8-10 is obtained and the reaction is kept under stirring for 1-4 h at room temperature. After completion of the reaction, it is preferably washed with purified water and filtered off.
- This procedure generates nano and microparticles that contain within and on the surface conjugates rhEGF-rP64k bound by interactions between the positively charged groups of the particle and the COOs of the conjugate and between the negatively charged groups in the particle and the amines of the conjugate.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- rhEGF is replaced by one or more peptides that are part of rhEGF.
- This procedure generates nano and micro-particles that contain within and on the surface conjugates rhEGF-rP64k bound by Electrostatic interactions between the positively charged groups on the particle and the COOs of the conjugate and between the negatively charged groups on the particle and the amines of the conjugate.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- rhEGF is replaced by one or more peptides that are part of rhEGF.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- the procedure generates nano and microparticles that contain on the surface rhEGF and rP64k molecules linked by interactions between the positively charged groups on the particle and the COO- of the proteins and between the negatively charged groups on the particle and the amino groups on the proteins.
- the recombinant rP64k protein is replaced by tetanus toxoid, KLH or another carrier protein.
- the present invention also comprises the replacement of the rP64k protein with one or more immunogenic peptides of natural or synthetic origin.
- the combinations described above favor the chronic treatment of cancer in tissues of epithelial origin, since they avoid the accumulation of substances foreign to the organism at the injection sites and their associated toxicity.
- the anti-EGF systems encompassed in the present invention use suitable pharmaceutical excipients. These include, but are not limited to: water for injections, sodium chloride, phosphorous and potassium salts, calcium chloride, sodium citrate and hydroxide, and EDTA. They can be inoculated to patients with cancer of epithelial origin in parenteral formulations of protein concentrations of 0.5 to 5 mg / mL and doses between 20-70 pL / kg or 20-70 pg of total proteins per kilogram or up to 5 mg of total proteins, being more recommended 30-60 pg / kg.
- the dose to be applied of the inorganic component defined in the present invention will be 2-4.5 mg / kg, being more recommended 3-4 mg / kg, as long as it is kept within the limits of the approved doses for its use in humans, intramuscularly or subcutaneously.
- FIG. 1 X-Ray Diffraction Pattern: A) Amorphous HAp particles, obtained in the present invention. B) HAp JCPDS reference standard: PDF Ref. 09-0432.
- Figure 3 Size of the amorphous HAp particles obtained in the present invention, determined by transmission electron microscopy. A) Image of the particles with 25000 X magnification. B) Image of the particles with 500000 X magnification. C) Particle size distribution.
- Figure 6 Characterization of the HAp-rhEGF-rP64k system by: A) SDS-PAGE electrophoresis: 1 -Molecular mass pattern, 2-Positive control of rhEGF-rP64k conjugate prepared according to the invention US 8,778,879, 3- HAp-rhEGF- system rP64k. B) Western Blot profile: 1 - RhEGF-rP64k conjugate positive control, 2- HAp-rhEGF-rP64k system.
- Figure 7. Anti-EGF antibody response in C57BL / 6 mice immunized with the covalently linked HAp-rhEGF-rP64k system and with the control group (Montanide-rhEGF-rP64k).
- Figure 8 Relationship of antibody subclasses (lgG2b + lgG2c) / lgG1, contained in sera from C57BL / 6 mice immunized with the HAp-rhEGF-rP64k systems and with the control group (Montanide-rhEGF-rP64k).
- Figure 9 Photograph of the effect of the HAp-rhEGF-rP64k and Montanide-rhEGF-rP64k systems on the injection sites in BALB / c mice.
- Figure 11 Relationship of antibody subclasses (lgG2a + lgG2b) / lgG1, contained in sera from C57BL / 6 mice immunized with the HAp-rhEGF-rP64k system combined with VSSP and with rhEGF-rP64k encapsulated in DRV's liposomes.
- Figure 14 Characterization of the HAp-PI system by: A) SDS-PAGE electrophoresis: 1- Molecular mass pattern, 2-Positive control of rP64k 3- Positive control of rhEGF 4- HAp-PI system covalently linked and B) Western Blot Profile: 1 - rP64k positive control, 2- HAp-PI system.
- Figure 16 Characterization of the HAp-CM system by: A) SDS-PAGE electrophoresis 1 - Molecular mass standard, 2-Positive control of rhEGF-rP64k conjugate prepared according to the invention US 8,778,879, 3- Covalently linked HAp-CM system and B) Western Blot Profile 1 - RhEGF-rP64k conjugate positive control, 2- HAp-CM system.
- Figure 18 Relationship of antibody subclasses (lgG2b + lgG2c) / lgG1, contained in sera from C57BL / 6 mice immunized with the HAp-rhEGF-rP64k, HAp-PI and HAp-CM systems and with the Montanide-rhEGF-rP64k control. .
- amorphous HAp nanoparticles coated with sodium citrate were obtained.
- a solution A was prepared, made up of CaCh 0.05 mol / L and sodium citrate, with a molar ratio: sodium / calcium citrate of 4: 1.
- the Fourier transform infrared (FT-IR) spectra of the nanoparticles (A) and the sodium citrate used as control (B) are shown in Figure 2.
- the bands observed in 1090, 1030, 962, 604, 561 and 472 cnr 1 in the spectrum of nanoparticles confirmed the presence of the phosphate groups corresponding to HAp.
- at 3400 cnr 1 there is a broad band attributed to wastewater and OH- groups. Bands of citrate carboxylate groups at 1610 and 1413 cnr 1 were also observed in both spectra, confirming the presence of this ligand on the surface.
- the nanoparticles showed a spherical morphology ( Figures 3A and 3B), with an average size of 62 ⁇ 13 nm ( Figure 3C), determined by transmission electron microscopy.
- Figure 4 a 6.2% loss of mass was found at temperatures greater than 200 ° C ( Figure 4), which is related to the presence of sodium citrate on the surface of the nanoparticles.
- the temperature range analyzed was between 25 ° C and 1000 ° C with a heating rate of 20 K / min, using an argon flow of 60 mL / min.
- the amorphous HAp nanoparticles were treated with a sterile EDC solution maintaining an EDC / HAp mass ratio of 2: 1 for one hour, under controlled environmental conditions. The suspension was then centrifuged at 6708 gravities and excess EDC was removed.
- Example 2 Obtaining the HAp-rhEGF-rP64k system by covalently binding amorphous HAp nanoparticles to the rhEGF-rP64k conjugate
- amorphous HAp nanoparticles obtained and activated according to Example 1 were mixed under controlled environmental conditions, with a sterile solution of phosphate buffer (PBS) of pH 7 ⁇ 0.3, which contained the chemical conjugate rhEGF-rP64k obtained according to methodology described in the invention US 8,778,879, at a mass ratio of rhEGF-rP64k / HAp of 1:
- PBS phosphate buffer
- the HAp-rhEGF-rP64k system was obtained, which was dispersed with EDTA, the medium conditions were adjusted to pH 7 ⁇ 0.3 and protein concentration to 1 ⁇ 0.2 mg / mL, with sterile solutions of PBS and hydroxide of sodium.
- the DLS test indicated the presence of nano-particles of medium hydrodynamic diameter
- the nano-particulate system obtained by the procedure explained above, was characterized by SDS-PAGE electrophoresis and Western Blot ( Figure 6). Electrophoresis showed a band pattern similar to the positive control of the rhEGF-rP64k conjugate (predominant bands with molecular mass equal to or greater than 66 kDa), indicating its presence in the system. In the Western Blot assay, a band similar to the free rhEGF-rP64k conjugate control was observed, determining the existence of rhEGF in conjugates with a molecular mass greater than 200 kDa. With this analysis it was shown that the rhEGF-rP64k conjugate bound to the nanoparticles maintained its structural and functional integrity as it continues to be recognized by anti-EGF antibodies.
- Example 3 The HAp-rhEGF-rP64k system generates a humoral response against EGF with no visible adverse effects at injection sites.
- a four-dose immunization schedule was applied (days: 0, 14, 28 and 42). Two days before starting the immunization protocol and on days 35 and 56, both groups of mice had their total IgG antibody titers against EGF determined by ELISA.
- the EGF-specific (IgG2b + IgG2c) / IgG1 ratio was also determined in immune sera at 56 days.
- Statistical analysis was performed using the Kruskal-Wallis mean comparison test, unequal letters indicate statistically significant differences (p ⁇ 0.05).
- the FIAp-rhEGF-rP64k system generated anti-EGF antibodies, which were determined in the immune serum at a dilution of 1 / 10,000 at 56 days (Figure 7).
- This result demonstrates that the binding of the rhEGF-rP64k conjugate to the particle does not affect its integrity, and that HAp enhances an anti-EGF humoral response despite being significantly lower than the control group.
- the ratio (lgG2b + lgG2c) / lgG1 showed that there are no statistically significant differences between the response produced by the HAp-rhEGF-rP64k system and the control (Montanide-rhEGF-rP64k) (Figure 8).
- humoral responses prevail (Th2), which makes them very appropriate for EGF depletion, as part of the treatment of cancer of epithelial origin.
- mice were treated with the anti-EGF system obtained in Example 2 (HaP-rhEGF-rP64k) and the same number of mice with the Montanide-rhEGF-rP64k control.
- the vaccination schedule was similar to that described above.
- photographic images were taken of the injection sites in the mice of the two treated groups.
- Figure 9A it can be seen that the mice of the control group presented accumulations of mineral oil at the injection sites, coming from the Montanide.
- Example 4 The combination of the HAp-rhEGF-rP64k system with particulate adjuvants generates an anti-EGF IgG antibody response and induces a Th1-type response pattern.
- Group 1 63 pg of proteins of the vaccine composition described in US 8,778,879 (Montanide-rhEGF-rhP64k) (Positive control).
- Group 2 63 pg of proteins from the HAp-rhEGF-rP64k system with 100 pg of proteins from the nano-particulate adjuvant VSSP.
- Group 3 31, 5 pg protein Hap-rhEGF-rP64K and 31, 5 pg of conjugate rhEGF- rP64K system, encapsulated in liposomal vesicles (DRV 's) derived by dehydration-rehydration (Kirby and Gregoriadis, Biotechnology methodology, (1984) 2: 979-984).
- DBV 's liposomal vesicles
- Immunizations were performed on days 0, 14, 28 and 42. Blood was drawn two days before starting the protocol and on days 35 and 56 and with the serum obtained, the titers of total anti-IgG antibodies were determined by ELISA. EGF. The relationship (IgG2b + IgG2c) / IgG1 specific to EGF in the sera was also determined on day 56. Statistical analysis was performed using the Kruskal-Wallis mean comparison test, unequal letters indicate statistically significant differences (p ⁇ 0, 05).
- Example 5 Maintenance of anti-EGF IgG antibody response by the HAp-rhEGF-rP64k system, previously induced with Montanide-rhEGF-rP64k
- mice were immunized with 63 pg of proteins contained in the system described in the invention US 8,778,879 (Montanide-rhEGF-rhP64k).
- Group 2 Mice were immunized on day 0 with 63 pg of proteins contained in the Montanide-rhEGF-rhP64k system and the rest of the immunizations with the same amount of proteins contained in the HAp-rhEGF-rP64k system.
- Group 3 Mice were immunized on days 0 and 14 with 63 pg of proteins contained in the Montanide-rhEGF-rhP64k system and the rest of the immunizations with the same amount of proteins contained in the HAp-rhEGF-rP64k system. Two days prior to the first immunization, the preimmune serum was extracted and after 35, 56 and 84 days the immune sera were extracted and the anti-EGF IgG antibody titers were quantified by ELISA.
- Anti-EGF antibody titers were observed at the three times studied, without statistical differences between the three groups, being observed in the dilution of 1/50000 on day 35 and 1/100000 on days 56 and 84 ( Figure 12).
- the inoculation of the FIAp-rhEGF-rP64k system maintained the response of anti-EGF antibodies of the IgG type induced by Montanide-rhEGF-rP64k, during the entire period of time studied. This supports the feasibility of substituting Montanide for HAp as an adjuvant of the rhEGF-rP64k conjugate in the maintenance phase of the anti-EGF immune response and its application in the chronic treatment of cancer of epithelial origin.
- Example 6 Construction of the HAp-PI system by covalently binding the rhEGF and rP64k proteins on the surface of the amorphous HAp nanoparticles
- Figure 13 shows the particle size profile measured by DLS.
- the mean diameter was 111.2 nm, with a polydispersity index of 0.347.
- the system obtained was similar to that generated in Example 2 in terms of its size, polydispersity and DLS profiles. This indicates that the binding of rhEGF and rP64k to HAp nanoparticles without being bound to each other, produced a dispersion similar to that obtained with the conjugate rhEGF-rP64k.
- Example 7 Construction of the HAp-CM system on the surface of amorphous HAp nanoparticles by multiple conjugation of the rhEGF and rP64k proteins
- Example 8 The new systems built on HAp nanoparticles generate anti-EGF IgG antibody responses producing fewer epidermal lesions at the injection site.
- mice Three groups of five C57BL / 6 mice each were immunized with 63 pg of proteins, contained in the following systems:
- Immunizations were performed on days 0, 14, 28 and 42. Blood was drawn two days before starting the protocol and on days 35 and 56 and with the serum obtained, the titers of total anti-IgG antibodies were determined by ELISA. EGF. The EGF-specific (IgG2b + IgG2c) / IgG1 ratio was also determined in the sera on day 56. Statistical analysis was performed using the Kruskal-Wallis mean comparison test, unequal letters indicate statistically significant differences (p ⁇ 0.05).
- the HAp-rP64k and HAp-CM systems generated anti-EGF antibodies that were determined in the immune serum up to a dilution of 1/10000 and in the HAp-PI system up to a dilution of 1/8000 on days 35 and 56 ( Figure 17 ).
- the results obtained by SDS-PAGE and Western Blot were confirmed (Examples 6 and 7) and it was shown that the systems built on HAp nanoparticles are immunogenic, despite the fact that rhEGF is in the context of a covalent bond. with the rhP64k and the HAp particle. This development constitutes evidence that it is feasible to produce systems that generate an anti-EGF immune response without requiring to chemically bind rhEGF with a carrier protein.
- Figures 19B and C show longitudinal (B) and transverse (C) fibers of muscle tissue adjacent to the site of inoculation with invasion of a fibroblast repair tissue reaction.
- Figures 19D-F belonging to mice treated with the new systems object of the present invention, normal structure of the inoculation site and its adjacent muscle tissue is observed.
- D HAp-rhEGF- rP64k.
- E HAp-CM.
- F HAp-PI.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022575761A JP2023529895A (ja) | 2020-06-09 | 2021-05-31 | がん治療のための無機ナノ粒子をベースとしたワクチン組成物 |
BR112022024495A BR112022024495A2 (pt) | 2020-06-09 | 2021-05-31 | Composições de vacina baseadas em nanopartículas inorgânicas para tratamento de câncer |
AU2021294904A AU2021294904A1 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
EP21761969.1A EP4162949A2 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
CA3180605A CA3180605A1 (en) | 2020-06-09 | 2021-05-31 | Vaccine compositions based on inorganic nanoparticles for cancer treatment |
MX2022015460A MX2022015460A (es) | 2020-06-09 | 2021-05-31 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cancer. |
KR1020227046420A KR20230022891A (ko) | 2020-06-09 | 2021-05-31 | 무기 나노입자를 기초로 한 암치료용 백신 조성물 |
US17/928,806 US20230226163A1 (en) | 2020-06-09 | 2021-05-31 | Inorganic nanoparticle-based vaccine compositions for cancer treatment |
CN202180041521.XA CN116033918A (zh) | 2020-06-09 | 2021-05-31 | 用于治疗癌症的基于无机纳米颗粒的疫苗组合物 |
CONC2022/0019141A CO2022019141A2 (es) | 2020-06-09 | 2022-12-28 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CUCU-2020-0032 | 2020-06-09 | ||
CU2020000032A CU20200032A7 (es) | 2020-06-09 | 2020-06-09 | Composiciones vacunales basadas en nano-partículas de fosfatos de calcio para el tratamiento del cáncer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021259397A2 true WO2021259397A2 (es) | 2021-12-30 |
WO2021259397A3 WO2021259397A3 (es) | 2022-04-14 |
Family
ID=77518870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2021/050005 WO2021259397A2 (es) | 2020-06-09 | 2021-05-31 | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230226163A1 (es) |
EP (1) | EP4162949A2 (es) |
JP (1) | JP2023529895A (es) |
KR (1) | KR20230022891A (es) |
CN (1) | CN116033918A (es) |
AR (1) | AR122547A1 (es) |
AU (1) | AU2021294904A1 (es) |
BR (1) | BR112022024495A2 (es) |
CA (1) | CA3180605A1 (es) |
CO (1) | CO2022019141A2 (es) |
CU (1) | CU20200032A7 (es) |
MX (1) | MX2022015460A (es) |
TW (1) | TW202214288A (es) |
WO (1) | WO2021259397A2 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003218271A1 (en) * | 2002-04-18 | 2003-11-03 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
CU23652A1 (es) * | 2007-06-29 | 2011-05-27 | Centro Inmunologia Molecular | Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención |
WO2020051566A1 (en) * | 2018-09-07 | 2020-03-12 | Immunotope, Inc. | Vaccines with enhanced immune response and methods for their preparation |
WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
-
2020
- 2020-06-09 CU CU2020000032A patent/CU20200032A7/es unknown
-
2021
- 2021-05-31 CN CN202180041521.XA patent/CN116033918A/zh active Pending
- 2021-05-31 MX MX2022015460A patent/MX2022015460A/es unknown
- 2021-05-31 US US17/928,806 patent/US20230226163A1/en active Pending
- 2021-05-31 CA CA3180605A patent/CA3180605A1/en active Pending
- 2021-05-31 KR KR1020227046420A patent/KR20230022891A/ko unknown
- 2021-05-31 BR BR112022024495A patent/BR112022024495A2/pt unknown
- 2021-05-31 WO PCT/CU2021/050005 patent/WO2021259397A2/es unknown
- 2021-05-31 AU AU2021294904A patent/AU2021294904A1/en active Pending
- 2021-05-31 EP EP21761969.1A patent/EP4162949A2/en active Pending
- 2021-05-31 JP JP2022575761A patent/JP2023529895A/ja active Pending
- 2021-06-03 TW TW110120236A patent/TW202214288A/zh unknown
- 2021-06-04 AR ARP210101535A patent/AR122547A1/es unknown
-
2022
- 2022-12-28 CO CONC2022/0019141A patent/CO2022019141A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023529895A (ja) | 2023-07-12 |
KR20230022891A (ko) | 2023-02-16 |
BR112022024495A2 (pt) | 2023-01-24 |
MX2022015460A (es) | 2023-02-01 |
WO2021259397A3 (es) | 2022-04-14 |
AR122547A1 (es) | 2022-09-21 |
TW202214288A (zh) | 2022-04-16 |
AU2021294904A1 (en) | 2023-02-02 |
CA3180605A1 (en) | 2021-12-30 |
EP4162949A2 (en) | 2023-04-12 |
CO2022019141A2 (es) | 2022-12-30 |
CN116033918A (zh) | 2023-04-28 |
CU20200032A7 (es) | 2022-01-13 |
US20230226163A1 (en) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Metal‐organic‐framework‐based vaccine platforms for enhanced systemic immune and memory response | |
ES2843509T3 (es) | Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina | |
TW201622743A (zh) | 免疫原醣肽、包含該醣肽之組合物及其用途 | |
CN103648587B (zh) | 疫苗递送方法 | |
JP2011190278A (ja) | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 | |
JP5112081B2 (ja) | 免疫刺激性ポリホスファゼン化合物 | |
JP6111245B2 (ja) | 水酸化アルミニウムナノ粒子を含むワクチン組成物 | |
WO2008031126A1 (en) | Multi-component tumour vaccine | |
US20240131152A1 (en) | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
WO2023123959A1 (zh) | 一种铝锰复合纳米晶及其制备方法和应用 | |
WO2021259397A2 (es) | Composiciones vacunales basadas en nano-particulas inorganicas para el tratamiento del cáncer | |
EA045818B1 (ru) | Композиции вакцины для лечения рака, основанные на неорганических наночастицах | |
Marasini et al. | Poly-L-lysine-coated nanoparticles are ineffective in inducing mucosal immunity against group a streptococcus | |
ES2241122T3 (es) | Formulaciones de inmunopotenciacion para uso como vacunas. | |
JP2023522592A (ja) | 抗原性部位とリポソーム調製物とを含む免疫原性組成物、当該組成物を作製する方法、薬物として使用するための、特にワクチンとして使用するための、当該組成物 | |
Alshanqiti et al. | Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid | |
US20130011430A1 (en) | HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER | |
He et al. | Cistanche deserticola polysaccharide-functionalized dendritic fibrous nano-silica as oral vaccine adjuvant delivery enhancing both the mucosal and systemic immunity | |
Rosales-Mendoza et al. | Silica-based mucosal nanovaccines | |
US20240197856A1 (en) | Immunogenic composition and uses thereof | |
Yu et al. | The pH-responsive zeolitic imidazolate framework nanoparticle as a promising immune-enhancing adjuvant for anti-caries vaccine | |
JP2002512619A (ja) | 横隔膜下からの全身経路に使用するための抗ヘリコバクターワクチン組成物、および粘膜/非経口複合免疫法 | |
JP2009535428A (ja) | 長時間作用性抗体を製造するためのヒト絨毛性ゴナドトロピン(hCG)ワクチンの送達方法 | |
Frère et al. | Peptide Nanostructured Conjugates for Therapeutics: The Example of P140 Peptide for the Treatment of Systemic Lupus Erythematosus | |
Clauson | Viral Mimicking Iron-Oxide Nanoplatforms for Highly Efficient Lymph Node Delivery and Lymphocyte Activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3180605 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022575761 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022024495 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227046420 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021761969 Country of ref document: EP Effective date: 20230109 |
|
ENP | Entry into the national phase |
Ref document number: 112022024495 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221130 |
|
ENP | Entry into the national phase |
Ref document number: 2021294904 Country of ref document: AU Date of ref document: 20210531 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21761969 Country of ref document: EP Kind code of ref document: A2 |